Background: Older adults (OA) with advanced cancer (AC) undergoing phase I clinical trials (PICT) have poor prognosis. There are no studies which describe symptoms experienced by OA. Methods: Retrospective chart review of PICT participants >60 years. OA were compared by age (>65 vs 60-65) and by number of symptoms (>3 vs ≤3). Results: N = 56. Mean age = 67.09; 48.21% female. Median life-expectancy = 5 months (interquartile range = 2-9 months); 80.36% had pain; of those 64% without pain scale. Most did not have interdisciplinary professionals or hospice referrals. Older adults with >3 symptoms had more admissions (37.5% vs 14.29%; P = .0335), complications (46.43% vs 16.07%; P = .0026), and greater decline in functional status (24 participants >3 symptoms vs 8; P = .0173). There were no significant differences comparing OA by age. Conclusions: Older adults enrolled in PICT with more symptoms may sacrifice QOL for experimental treatment.
RobertsTGJrGoulartBHSquitieriL. Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA. 2004;292(17):2130–2140.
2.
ZamboniBAYothersGChoiM. Conditional survivial and the choice of conditioning set for patients with colon cancer: an analysis of NSABP trials C-03 through C-07. J Clin Oncol. 2010:28(15):2544–2548. Epub 2010 Apr 20
3.
JanishLMickRSchilskyRL. Prognostic factors for survival in patients treated in phase I clinical trials. Cancer. 1994;74(7):1965–1973.
4.
BachelotTRay-CoquardICatimelG. Multivariable analysis or prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials. Ann Oncol. 2000;11(2):151–156.
5.
FinlayELuHLHendersonHO'DwyerPJCasarettDJ. Do phase 1 patients have greater needs for palliative care compared with other cancer patients?. Cancer. 2009;115(2):446–453.
6.
LoConteNKSmithMAlbertiD. Amongst eligible patients, age and comorbidity do not predict for dose-limiting toxicity from phase I chemotherapy. Cancer Chemother Pharmacol. 2010;65(4):775–780. Epub 2009 Aug 1
7.
OkenMMCreechRHTormeyDC. Toxicity and response criteria of The Eastern cooperative oncology group. Am J Clin Oncol. 1982;5(6):649–655.
8.
SillimanRAGuadagnoliEWeitbergABMorV. Age as a predictor of diagnostic and initial treatment intensity in newly diagnosed cancer patients. J Gerontol. 1989;44(2):M46–M50.
9.
FentimanISTirelliUMonfardiS. Cancer in the elderly: why so badly treated?. Lancet. 1990;335(8696):1020–1022.
10.
BeggCBCohenJLEllertonJ. Are the elderly predisposed to toxicity from cancer chemotherapy? An investigation using data from the Eastern Cooperative Oncology Group. Cancer Clin Trials. 1980;3(4):369–374.
11.
ChristmanKMussHBCaseLDStanleyV. Chemotherapy of metastatic breast cancer in the elderly: the Piedmont Oncology Association experience. JAMA. 1992;268(1):57–62.
12.
CascinuSDel FerroECatalanoG. Toxicity and therapeutic response to chemotherapy in patients aged 70 years or older with advanced cancer. Am J Clin Oncol. 1996;19(4):371–374.
13.
MonfardiniSAversaSMZoliV. Vinorelbine and prednisone in frail elderly patients with intermediate-high grade non-Hodgkin's lymphomas. Ann Oncol. 2005;16(8):1352–13528. Epub 2005 Apr 27
14.
ReddyNYuJFakihMG. Toxicities and survival among octogenarians and nonagenarians with colorectal cancer treated with chemotherapy or concurrent chemoradiation therapy. Clin Colorectal Cancer. 2007;6(5):362–366.
15.
ByockI. Palliative care and the ethics of research: Medicare, hospice, and phase I trials. J Support Oncol. 2003;1(2):139–141.
16.
ByockIMilesSH. Hospice benefits and phase I cancer trials. Ann Internal Med. 2003;138(4):335–337.
17.
PaprsteinH. Hospice patients in clinical cancer treatment trials. Clin J Oncol Nurs. 2005;9(6):729–732.
18.
FoxELandrum-McNiffKZhongZfor the SUPPORT Investigators. Evaluation of prognostic criteria for determining hospice eligibility in patients with advanced lung, heart, or liver disease. JAMA. 1999;282(17):1638–1645.
